SLGL vs. SCYX, BRNS, IFRX, BNTC, CMRX, TLSA, VTVT, ASMB, ONCY, and PYRGF
Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include SCYNEXIS (SCYX), Barinthus Biotherapeutics (BRNS), InflaRx (IFRX), Benitec Biopharma (BNTC), Chimerix (CMRX), Tiziana Life Sciences (TLSA), vTv Therapeutics (VTVT), Assembly Biosciences (ASMB), Oncolytics Biotech (ONCY), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical preparations" industry.
Sol-Gel Technologies (NASDAQ:SLGL) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
SCYNEXIS has a net margin of 72.18% compared to Sol-Gel Technologies' net margin of -1,329.13%. SCYNEXIS's return on equity of 112.89% beat Sol-Gel Technologies' return on equity.
SCYNEXIS received 357 more outperform votes than Sol-Gel Technologies when rated by MarketBeat users. Likewise, 70.24% of users gave SCYNEXIS an outperform vote while only 63.25% of users gave Sol-Gel Technologies an outperform vote.
SCYNEXIS has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than SCYNEXIS, indicating that it is currently the more affordable of the two stocks.
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 2.9% of SCYNEXIS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Sol-Gel Technologies presently has a consensus target price of $6.50, suggesting a potential upside of 722.78%. SCYNEXIS has a consensus target price of $15.00, suggesting a potential upside of 535.59%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Sol-Gel Technologies is more favorable than SCYNEXIS.
In the previous week, Sol-Gel Technologies had 12 more articles in the media than SCYNEXIS. MarketBeat recorded 15 mentions for Sol-Gel Technologies and 3 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.45 beat Sol-Gel Technologies' score of -0.12 indicating that SCYNEXIS is being referred to more favorably in the news media.
Sol-Gel Technologies has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, SCYNEXIS has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500.
Summary
SCYNEXIS beats Sol-Gel Technologies on 12 of the 18 factors compared between the two stocks.
Get Sol-Gel Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sol-Gel Technologies Competitors List
Related Companies and Tools
